Research To Practice

•

チャンネル • 10個の番組

科学

科学

アップデート：毎月
科学

科学

アップデート：毎週
科学

科学

アップデート：月2回
科学

科学

アップデート：毎週
科学

科学

アップデート：隔週
科学

科学

アップデート：毎週
科学

科学

アップデート：毎週

3月30日

Diabetology in Breast Cancer — Managing Hyperglycemia in Patients with Breast Cancer Receiving Agents Targeting the PI3K/AKT/PTEN Pathway

Ms Jaime Carroll from Mayo Clinic in Rochester, Minnesota, Professor Giuseppe Curigliano from the European Institute of Oncology in Milan, Italy, Dr Marie E McDonnell from Brigham and Women’s Hospital in Boston, Massachusetts, and Dr Hope S Rugo from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss the incidence, prevention and management of hyperglycemia in breast cancer patients receiving PI3K/AKT/PTEN inhibitors. CME information and select publications here.

3月30日

•

1時間16分
4日前

CELMoDs for Multiple Myeloma — Microlearning Activity 2 with Dr Paul G Richardson

Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma. CME information and select publications here.

4日前

•

25分
4日前 · ビデオ

CELMoDs for Multiple Myeloma — Microlearning Activity 2 with Dr Paul G Richardson

Featuring perspectives from Dr Paul G Richardson, including the following topics: EXCALIBER-RRMM: A Phase III trial of iberdomide, daratumumab and dexamethasone for relapsed/refractory multiple myeloma (0:00) Lonial S et al. EXCALIBER-RRMM: A phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma. Future Oncol 2025;21(14):1761-9. Abstract Phase III SUCCESSOR-1 and SUCCESSOR-2 studies evaluating mezigdomide-based regimens for relapsed/refractory multiple myeloma (8:24) Richardson PG et al. A phase III, two-stage, randomized study of mezigdomide, bortezomib, and dexamethasone (MeziVd) versus pomalidomide, bortezomib, and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-1. SOHO 2023;Abstract MM-372. Richardson PG et al. A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2. ASCO 2023;Abstract TPS8070. EMN26: A Phase II study of maintenance therapy with iberdomide after autologous stem-cell transplantation for newly diagnosed multiple myeloma (13:34) van de Donk NWCJ et al. Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: An update from the phase 2 EMN26 trial. ASH 2025;Abstract 101. STOMP: A Phase I study of selinexor, mezigdomide and dexamethasone for patients with relapsed/refractory multiple myeloma who experienced relapse with or are ineligible for T-cell-redirecting therapy (24:53) Mo C et al. Selinexor, mezigdomide, and dexamethasone in patients with relapsed/refractory multiple myeloma who relapsed or are ineligible for T-cell–redirecting therapy: Stomp Phase 1 results. ASH 2025;Abstract 4010. CME information and select publications

4日前 · ビデオ

•

25分
1月8日

Antibody-Drug Conjugates for Breast Cancer — Proceedings from a San Antonio 2025 Symposium Series

Dr Javier Cortés from the International Breast Cancer Center in Barcelona, Spain, Dr Rita Nanda from the University of Chicago, Prof Peter Schmid from Barts Cancer Institute in London, United Kingdom, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood discuss key clinical data with antibody-drug conjugates for metastatic breast cancer and their expert perspectives surrounding its clinical applications. CME information and select publications here.

1月8日

•

1時間30分
4月7日

Desmoid Tumors — Microlearning Activity 2 with Dr Ravin Ratan

Dr Ravin Ratan from The University of Texas MD Anderson Cancer Center in Houston discusses available clinical data with treatment approaches for desmoid tumors, alongside clinical cases illustrating real-world application. CME information and select publications here.

4月7日

•

28分
1月27日

Endocrine-Based Therapy for HR-Positive Breast Cancer — Proceedings from a San Antonio 2025 Symposium Series

Dr Angela DeMichele from the Abramson Cancer Center in Philadelphia, Pennsylvania, Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, Dr Erica Mayer from Dana-Farber Cancer Institute in Boston, Massachusetts, Dr Hope S Rugo from City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Seth Wander from Massachusetts General Hospital in Boston discuss real-world cases and recent clinical data surrounding the management of HR-positive breast cancer. CME information and select publications here.

1月27日

•

2時間1分
3月31日

AKT Inhibition in Prostate Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers Symposium

Prof Karim Fizazi from the Centre Oscar Lambret in Lille, France, Dr Daniel George from the Duke Cancer Institute in Durham, North Carolina, and moderator Dr Elisabeth I Heath from Mayo Clinic in Rochester, Minnesota, discuss the future role of AKT inhibition in prostate cancer. CME information and select publications here.

3月31日

•

1時間29分
3月18日

Breast Cancer — 5-Minute Journal Club Issue 2 with Dr Lajos Pusztai: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays

Dr Lajos Pusztai from Yale Cancer Center in New Haven, Connecticut, discusses recent developments with circulating tumor DNA assays in the management of breast cancer. CME information and select publications here.

3月18日

•

30分
3月30日

AKT Inhibition in Prostate Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers Symposium

Prof Karim Fizazi from the Centre Oscar Lambret in Lille, France, Dr Daniel George from the Duke Cancer Institute in Durham, North Carolina, and moderator Dr Elisabeth I Heath from Mayo Clinic in Rochester, Minnesota, discuss the future role of AKT inhibition in prostate cancer. CME information and select publications here.

3月30日

•

1時間29分
2025/12/19

Urothelial Bladder Cancer and Prostate Cancer — Highlights from the 2025 ESMO Annual Meeting

Dr Terence Friedlander from the UCSF Helen Diller Family Comprehensive Cancer Center and Dr Rana R McKay from the UC San Diego Moores Cancer Center summarize the treatment landscape for prostate and urothelial bladder cancer and discuss the implications of clinical findings recently presented at the ESMO Congress 2025. CME information and select publications here.

2025/12/19

•

1時間2分

CME education for oncology clinicians. Medical oncologist Dr Neil Love interviews clinical investigators on new research and practical application to general medical oncology practice.